LAVA Therapeutics B.V. [•] Common Shares, Nominal Value €0.12 Underwriting AgreementUnderwriting Agreement • March 18th, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations • New York
LAVA Therapeutics B.V., a private company with limited liability organized under the laws of The Netherlands (besloten vennootschap met beperkte aansprakelijkheid) that is expected to convert into a public limited company organized under the laws of The Netherlands (naamloze vennootschap) at or immediately prior to the closing of the public offering of the Common Shares (as defined below) contemplated hereby (the “Company”), proposes to issue and sell to the several underwriters listed in Schedule 1 hereto (the “Underwriters”), for whom you are acting as representatives (the “Representatives”), an aggregate of [•] common shares, nominal value €0.12 per share, of the Company (the “Underwritten Shares”) and, at the option of the Underwriters, up to an additional [•] common shares of the Company (the “Option Shares”). The Underwritten Shares and the Option Shares are herein referred to as the “Common Shares”. The common shares of the Company to be outstanding after giving effect to the sa
INDEMNIFICATION AGREEMENT between [name] as the Officer and LAVA Therapeutics N.V. as the CompanyIndemnification Agreement • March 18th, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
EXECUTION COPY AMENDED AND RESTATED SHAREHOLDERS AGREEMENT BETWEEN DATED 15 SEPTEMBER 2020Shareholders Agreement • March 18th, 2021 • LAVA Therapeutics BV • Pharmaceutical preparations
All parties to this Agreement are together referred to as the Parties and each individually also as a Party. The parties mentioned under (1) through (13) are hereinafter collectively referred to as the Shareholders.
